A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

Duramed Research109 enrolled

Overview

This study is being conducted to evaluate the efficacy of a 91-day extended cycle oral contraceptive compared to placebo for decreasing the frequency and severity of menstrually-related migraine headaches.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

109

Conditions

Migraine

Interventions

91-day Levonorgestrel Oral ContraceptiveDRUG

91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.

PlaceboDRUG

1 tablet daily to match experimental arm

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 34 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Premenopausal, non-pregnant, non-lactating * History of migraine headaches without aura for at least 6 months * History of migraine headaches associated with menstruation * Others as directed by FDA-approved protocol Exclusion Criteria: * History of migraine headaches with aura or focal neurological symptoms * Any contraindication to the use of oral contraceptives * Others as dictated by FDA-approved protocol

Locations (22)

Teva Investigational Site

La Mesa, California, United States

Outcomes

Primary Outcomes

Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period

The number of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) through the end of the 91-day treatment period compared with Baseline (the 25- to 35-day baseline qualification period). Participants recorded the incidence, timing and intensity of migraines in a migraine diary during the prequalification period and throughout the 91-day treatment period.

Time frame: Baseline (25-35 days before Day 1) and Days 1-91

Secondary Outcomes

Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the First, Second and Third Months

The percentage of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) compared to Baseline at each month of the treatment period.

Time frame: Baseline, Month1, Month 2 and Month 3

Change From Baseline in Average Migraine Severity

Migraine severity was recorded by participants in the Baseline qualification diary and study migraine diary during the treatment period. Participants could report a severity of none (score = 0), mild (1), moderate (2), or severe (3). In general, if a headache was mild, daily activities could be resumed and little to no medication was taken. Moderate headaches required medication and effected daily activities. Severe headaches were debilitating and required medication. Average migraine severity is defined as the sum of the severity ratings divided by the total number of migraine episodes reported during the observation period (for example, Baseline, First Month, Second Month, Third Month, and 91-Day Treatment Period). A negative change from Baseline score indicates improvement in severity.

Time frame: Baseline and Month 1, Month 2 and Month 3

Percentage of Participants Who Required Rescue Medications During the Study Period

Participants recorded use of rescue medications for migraines in the migraine diary during the course of study treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Change From Baseline in Migraine Disability Assessment

The migraine disability assessment (MIDAS) test is used to determine how severely migraines affect a patient's life. Participants were asked five questions about how often their headaches limited their ability to go to work or school, to do household work or to do family or leisure activities in the past 3 months. The MIDAS score equals the sum of the days answered for each question and ranges from 0 (no disability) to approximately 270 (severe disability; the upper bound is dependent on the number of days a participant would plan to work or participate in other activities). The MIDAS score is classified into four grades of severity: * 0 to 5: MIDAS Grade I, Little or no disability * 6 to 10: MIDAS Grade II, Mild disability * 11 to 20: MIDAS Grade III, Moderate disability * 21+: MIDAS Grade IV, Severe disability

Time frame: Baseline and Week 15

Number of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation participant and which does not necessarily have to have a causal relationship with this treatment or clinical study. The following definitions were used to assess AE severity: Mild: Awareness of signs or symptoms, but they are easily tolerated; Moderate: Enough discomfort to cause interference with usual activity; Severe: Incapacitating, with inability to perform usual activity. Relationship to study drug was assessed as either: None: Causal relationship can be ruled out; Possibly: Causal relationship at least reasonably possible, i.e. relationship cannot be ruled out; Definitely: Causal relationship is certain. A serious adverse event (SAE) is one that met any one of the following criteria: * Fatal or life threatening * Requires or prolongs in patient hospitalization * Results in persistent or significant disability/incapacity * Congenital anomaly / birth defect * Important medical event.

Time frame: Up to 15 weeks